WallStreetZenWallStreetZen

NASDAQ: IMAB
I Mab Stock Forecast, Predictions & Price Target

Analyst price target for IMAB

Based on 3 analysts offering 12 month price targets for I Mab.
Min Forecast
$6.00+224.32%
Avg Forecast
$8.00+332.43%
Max Forecast
$10.00+440.54%

Should I buy or sell IMAB stock?

Based on 3 analysts offering ratings for I Mab.
Strong Buy
Strong Buy
1 analysts 33.33%
Buy
2 analysts 66.67%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their IMAB stock forecasts and price targets.

IMAB stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-04-12
lockedlocked$00.00+00.00%2024-03-18
lockedlocked$00.00+00.00%2024-03-18

1 of 1

Forecast return on equity

Is IMAB forecast to generate an efficient return?
Company
-142.68%
Industry
76.1%
Market
79%
IMAB's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is IMAB forecast to generate an efficient return on assets?
Company
-93.82%
Industry
30.96%
IMAB is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

IMAB earnings per share forecast

What is IMAB's earnings per share in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
-$2.13
Avg 2 year Forecast
-$1.70
Avg 3 year Forecast
-$1.77

IMAB revenue forecast

What is IMAB's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$3.0M-23.06%
Avg 2 year Forecast
$3.0M-23.06%
Avg 3 year Forecast
$3.0M-23.06%
IMAB's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

IMAB revenue growth forecast

How is IMAB forecast to perform vs Biotechnology companies and vs the US market?
Company
-7.77%
Industry
35%
Market
9.85%
IMAB's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
IMAB's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

IMAB vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
IMAB$1.85$8.00+332.43%Strong Buy
CNTX$2.00$6.50+225.00%Strong Buy
MDWD$16.08$28.00+74.13%Buy
GTHX$2.88$8.33+189.34%Buy
PRQR$1.80$3.17+75.94%Buy

I Mab Stock Forecast FAQ

Is I Mab Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: IMAB) stock is to Strong Buy IMAB stock.

Out of 3 analysts, 1 (33.33%) are recommending IMAB as a Strong Buy, 2 (66.67%) are recommending IMAB as a Buy, 0 (0%) are recommending IMAB as a Hold, 0 (0%) are recommending IMAB as a Sell, and 0 (0%) are recommending IMAB as a Strong Sell.

If you're new to stock investing, here's how to buy I Mab stock.

What is IMAB's earnings growth forecast for 2024-2026?

(NASDAQ: IMAB) I Mab's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.79%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.61%.

I Mab's earnings in 2024 is -$202,723,928.On average, 3 Wall Street analysts forecast IMAB's earnings for 2024 to be -$394,744,575, with the lowest IMAB earnings forecast at -$595,819,855, and the highest IMAB earnings forecast at -$200,462,755. On average, 3 Wall Street analysts forecast IMAB's earnings for 2025 to be -$314,930,700, with the lowest IMAB earnings forecast at -$410,206,193, and the highest IMAB earnings forecast at -$209,743,438.

In 2026, IMAB is forecast to generate -$329,148,707 in earnings, with the lowest earnings forecast at -$439,904,379 and the highest earnings forecast at -$220,880,258.

What is IMAB's revenue growth forecast for 2024-2026?

(NASDAQ: IMAB) I Mab's forecast annual revenue growth rate of -7.77% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.85%.

I Mab's revenue in 2024 is $3,823,513.On average, 1 Wall Street analysts forecast IMAB's revenue for 2024 to be $556,840,986, with the lowest IMAB revenue forecast at $556,840,986, and the highest IMAB revenue forecast at $556,840,986. On average, 1 Wall Street analysts forecast IMAB's revenue for 2025 to be $556,840,986, with the lowest IMAB revenue forecast at $556,840,986, and the highest IMAB revenue forecast at $556,840,986.

In 2026, IMAB is forecast to generate $556,840,986 in revenue, with the lowest revenue forecast at $556,840,986 and the highest revenue forecast at $556,840,986.

What is IMAB's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: IMAB) forecast ROA is -93.82%, which is lower than the forecast US Biotechnology industry average of 30.96%.

What is IMAB's Price Target?

According to 3 Wall Street analysts that have issued a 1 year IMAB price target, the average IMAB price target is $8.00, with the highest IMAB stock price forecast at $10.00 and the lowest IMAB stock price forecast at $6.00.

On average, Wall Street analysts predict that I Mab's share price could reach $8.00 by Apr 12, 2025. The average I Mab stock price prediction forecasts a potential upside of 332.43% from the current IMAB share price of $1.85.

What is IMAB's Earnings Per Share (EPS) forecast for 2024-2026?

(NASDAQ: IMAB) I Mab's current Earnings Per Share (EPS) is -$2.44. On average, analysts forecast that IMAB's EPS will be -$2.13 for 2024, with the lowest EPS forecast at -$3.21, and the highest EPS forecast at -$1.08. On average, analysts forecast that IMAB's EPS will be -$1.70 for 2025, with the lowest EPS forecast at -$2.21, and the highest EPS forecast at -$1.13. In 2026, IMAB's EPS is forecast to hit -$1.77 (min: -$2.37, max: -$1.19).

What is IMAB's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: IMAB) forecast ROE is -142.68%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.